AFT Pharmaceuticals started the commercialization program for its patented Maxigesic intravenous (IV) formulation signing a licensing agreement with Kyongbo Pharmaceutical Co. Ltd. ("Kyongbo Pharm"). Maxigesic IV (Paracetamol 1000mg+ Ibuprofen 300mg solution for infusion) has been developed as a line extension to Maxigesic tablets, for use post-operatively in hospitals to provide an alternative to opioid-based IV analgesics. A major Phase 3 clinical trial conducted in Texas and Maryland USA found that Maxigesic IV provided significantly better pain relief than either paracetamol (acetaminophen) IV or ibuprofen IV alone in the same doses and also reduced concomitant use of opioid analgesics. This is in line with first launches of Maxigesic IV starting from as early as the middle of financial year 2020. Importantly these first launches will also allow additional regulatory filings in a number of other territories in Asia and the Middle East which rely upon registration by key regulators such as the TGA in Australia.